Reward 500 Tiger-coinsOn Wednesday, $Eli Lilly(LLY)$ jumped 2.95% to close at $1,017.78 per share, hitting another record high and bringing its market capitalization close to the $1 trillion mark. Founded 147 years ago, this pharmaceutical giant is now writing a new chapter in wealth creation at an astonishing pace.
A quiet shift in market style is underway
The Dow Jones Industrial Average, representing traditional economy stocks, has been setting new highs, while tech-heavy growth sectors are showing signs of fatigue. Analysts attribute this rotation to growing concerns over an AI bubble and renewed appreciation for value stocks. This transition from “pure growth” to “pure value” began in August and is now accelerating.
The U.S. stock market is witnessing a clear style rotation. As “the young guns” — the long-dominant tech leaders — start to lose steam, “the old guard” — traditional blue chips — are taking the lead and setting fresh records.
On Tuesday, the divergence between sectors became the market’s defining feature: $Dow Jones(.DJI)$ surged strongly, marking its 16th record close of the year, while $NASDAQ(.IXIC)$ dominated by tech names, slipped into the red.
Healthcare shines: Why did LLY hit new highs?
Last Thursday, Trump announced a deal with Eli Lilly and Novo Nordisk to sharply cut prices on certain weight-loss drugs, including upcoming oral versions.
Under the agreement disclosed Thursday, starting in 2026, Medicare and Medicaid patients will be able to obtain Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy at a list price of $245 per month, with Medicare copays capped at $50.
$Goldman Sachs(GS)$ remains decisively bullish on Eli Lilly, citing several reasons:
Lilly’s Zepbound dominates both the reimbursement channel (60% vs. Wegovy’s 40%) and the cash-pay channel (85% vs. Wegovy’s 15%), positioning it to capture more upside from volume growth.
More importantly, Lilly received a Priority Review Voucher, allowing its oral GLP-1 drug, orforglipron, to potentially launch in Q1 2026 — earlier than previously expected (Q2–Q3).
Goldman estimates this could add at least $1 billion in incremental revenue for Lilly in 2026.
Beyond LLY — UNH and NVO also worth watching
In contrast, $Novo-Nordisk A/S(NVO)$ faces a tougher road ahead. Goldman noted that the company’s press release projected a “low single-digit” revenue impact in 2026 from the new pricing — an additional headwind on top of existing challenges.
The firm highlighted several obstacles: a 2-percentage-point drag from 2025 GTN impacts, low single-digit pressure from semaglutide generics abroad, and potential loss of Medicaid coverage in some U.S. states.
$UnitedHealth(UNH)$ also joined the healthcare rebound.
Shares surged 5.8% over two days as Reddit investor sentiment flipped from deeply bearish to bullish. Premiums at UnitedHealth rose 20–30% this year, while the core UnitedHealthcare segment posted 16% year-over-year revenue growth. Management raised 2025 adjusted EPS guidance to at least $16.25 and signaled accelerating growth into 2026.
With Eli Lilly breaking new highs, is Novo Nordisk now undervalued?
Do you believe UNH’s rebound has more room to run?
Besides healthcare, which other value stocks are climbing lately?
Leave your comments to win tiger coins, books and vouchers!
Comments
I get it, if you want to track a meme stock, by all means, look at Reddit because that would literally be a finger on the pulse.
In the medium term, I think Novo Nordisk can still go up, but I wonder if GLP1 will start losing steam, what with China catching up to that trend and likely to produce viable alternatives that will be cheaper.
I think UNH will similarly need the us government to prop them up to continue the ascend, otherwise it will likely lose steam.
AI is always climbing, anything and everything wants to be called AI to bask in the glory and cash in on the lucrative investments.
诺和诺德 $Novo-Nordisk A/S(NVO)$ 与此同时，看起来像是一个潜在的反弹游戏。随着定价压力和谨慎指导后预期的重置，利润率的任何稳定或口服索马鲁肽的更快推出都可能引发复苏。我会考虑加入蘸酱。
联合健康的 $联合健康(UNH)$ 反弹也很突出——强劲的保费增长和提高的每股收益指引显示出弹性。我认为它仍然有上升空间，特别是当投资者转向可靠的收益时。除了医疗保健之外，工业和消费必需品也在悄然走强。
@Tiger_comments @TigerStars
Riding the wave of Zepbound & Mounjaro, Lilly has become the darling of Wall Street. Its stock price pierced through the USD 1000 mark, buoyed by Trump era drug pricing deals. Investors see Lilly as politically aligned, commercially aggressive and structurally advantaged.
Novo Nordisk's stock has plunged over 40%, punished by pricing fears and slower US uptake.
Yet it remains profitable and more global intake. Ozempic, Wegovy have become global bestsellers. Wegovy recently gained FDA approval for reducing cardiovascular risk, expanding it's utility beyond weight loss.
I believe Novo Nordisk is undervalued compared to Lilly. Its fundamentals remain strong. Its recent stock decline may present a buying opportunity.
@Tiger_comments @TigerStars @TigerClub @CaptainTiger @Tiger_SG